Batoclimab

Batoclimab
Monoclonal antibody
Type	?
Identifiers
CAS Number	2187430-05-1;
UNII	C98V9UMX3D;

Batoclimab (also known as HBM9161 or HL161) is a fully human monoclonal antibody administered by subcutaneous injection. It works by inhibiting the neonatal fragment crystallizable receptor, which leads to a reduction in antibodies of the thyrotropin receptor. It is being developed to treat myasthenia gravis and thyroid eye disease.^[1]^[2]^[3]

References

^ Kahaly, George J.; Dolman, Peter J.; Wolf, Jan; Giers, Bert C.; Elflein, Heike M.; Jain, Amy P.; Srinivasan, Ashok; Hadjiiski, Lubomir; Jordan, David; Bradley, Elizabeth A.; Stan, Marius N.; Eckstein, Anja; Pitz, Susanne; Vorländer, Christian; Wester, Sara T.; Nguyen, John; Tucker, Nancy; Sales-Sanz, Marco; Feldon, Steven E.; Nelson, Christine C.; Hardy, Isabelle; Abia-Serrano, Maravillas; Tedeschi, Philip; Janes, Jonathan M.; Xu, Jing; Vue, Peter; Macias, William L.; Douglas, Raymond S. (30 June 2023). "Proof-of-Concept and Randomized, Placebo-Controlled Trials of an Fcrn Inhibitor, Batoclimab, for Thyroid Eye Disease". The Journal of Clinical Endocrinology and Metabolism. 108 (12): 3122–3134. doi:10.1210/clinem/dgad381. ISSN 1945-7197. PMC 10655547. PMID 37390454. S2CID 259303423.
^ Yan, Chong; Duan, Rui-Sheng; Yang, Huan; Li, Hai-Feng; Zou, Zhangyu; Zhang, Hua; Zhou, Hongyu; Li, Xiao-Li; Zhou, Hao; Jiao, Lidong; Chen, Jialin; Yin, Jian; Du, Qin; Lee, Michael; Chen, Yu; Chen, Xiaoxiang; Zhao, Chongbo (June 2022). "Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study". Neurology and Therapy. 11 (2): 815–834. doi:10.1007/s40120-022-00345-9. PMC 9095773. PMID 35412216.
^ Yap, Desmond Y. H.; Hai, Jojo; Lee, Paul C. H.; Zhou, Xueying; Lee, Michael; Zhang, Yu; Wang, Meng; Chen, Xiaoxiang (September 2021). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers". Clinical and Translational Science. 14 (5): 1769–1779. doi:10.1111/cts.13019. PMC 8504844. PMID 33742786.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Kahaly, George J.; Dolman, Peter J.; Wolf, Jan; Giers, Bert C.; Elflein, Heike M.; Jain, Amy P.; Srinivasan, Ashok; Hadjiiski, Lubomir; Jordan, David; Bradley, Elizabeth A.; Stan, Marius N.; Eckstein, Anja; Pitz, Susanne; Vorländer, Christian; Wester, Sara T.; Nguyen, John; Tucker, Nancy; Sales-Sanz, Marco; Feldon, Steven E.; Nelson, Christine C.; Hardy, Isabelle; Abia-Serrano, Maravillas; Tedeschi, Philip; Janes, Jonathan M.; Xu, Jing; Vue, Peter; Macias, William L.; Douglas, Raymond S. (30 June 2023). "Proof-of-Concept and Randomized, Placebo-Controlled Trials of an Fcrn Inhibitor, Batoclimab, for Thyroid Eye Disease". The Journal of Clinical Endocrinology and Metabolism. 108 (12): 3122–3134. doi:10.1210/clinem/dgad381. ISSN 1945-7197. PMC 10655547. PMID 37390454. S2CID 259303423.

[2] Yan, Chong; Duan, Rui-Sheng; Yang, Huan; Li, Hai-Feng; Zou, Zhangyu; Zhang, Hua; Zhou, Hongyu; Li, Xiao-Li; Zhou, Hao; Jiao, Lidong; Chen, Jialin; Yin, Jian; Du, Qin; Lee, Michael; Chen, Yu; Chen, Xiaoxiang; Zhao, Chongbo (June 2022). "Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study". Neurology and Therapy. 11 (2): 815–834. doi:10.1007/s40120-022-00345-9. PMC 9095773. PMID 35412216.

[3] Yap, Desmond Y. H.; Hai, Jojo; Lee, Paul C. H.; Zhou, Xueying; Lee, Michael; Zhang, Yu; Wang, Meng; Chen, Xiaoxiang (September 2021). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers". Clinical and Translational Science. 14 (5): 1769–1779. doi:10.1111/cts.13019. PMC 8504844. PMID 33742786.

[1]

[2]

[3]